An update on bronchiectasis.

M. A. Moreschi, Stanley Fiel

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Bronchiectasis is associated with heterogeneous predisposing conditions that cause abnormal dilatation and persistent inflammation in the bronchial tree and lung parenchyma. The disease remains a common cause of significant morbidity and mortality, especially when associated with hereditary disorders such as cystic fibrosis, ciliary dyskinesia, and immunodeficiency states. Recent investigations have focused on the inflammatory mediators involved in the pathogenesis of bronchiectasis. High-resolution computed tomography is now the diagnostic modality of choice and may also contribute to clinical management. Computed tomography and high-resolution computed tomography have identified bronchiectasis in individuals with HIV and alpha-1-antitrypsin deficiency. Early identification of predisposing disorders and aggressive management of symptoms has already been demonstrated by prolonged survival and decreased morbidity in cystic fibrosis patients, and similar management may benefit other populations with bronchiectasis. New treatments such as recombinant human DNase have been shown to improve pulmonary function and quality of life in cystic fibrosis patients and may prove useful in other chronic inflammatory lung disease.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalCurrent Opinion in Pulmonary Medicine
Volume1
Issue number2
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Bronchiectasis
Cystic Fibrosis
Tomography
Ciliary Motility Disorders
alpha 1-Antitrypsin Deficiency
Morbidity
Lung
Lung Diseases
HIV-1
Dilatation
Quality of Life
Inflammation
Survival
Mortality
Population
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Moreschi, M. A. ; Fiel, Stanley. / An update on bronchiectasis. In: Current Opinion in Pulmonary Medicine. 1995 ; Vol. 1, No. 2. pp. 119-124.
@article{e18006398c344ef395bbf537c5ec0b7e,
title = "An update on bronchiectasis.",
abstract = "Bronchiectasis is associated with heterogeneous predisposing conditions that cause abnormal dilatation and persistent inflammation in the bronchial tree and lung parenchyma. The disease remains a common cause of significant morbidity and mortality, especially when associated with hereditary disorders such as cystic fibrosis, ciliary dyskinesia, and immunodeficiency states. Recent investigations have focused on the inflammatory mediators involved in the pathogenesis of bronchiectasis. High-resolution computed tomography is now the diagnostic modality of choice and may also contribute to clinical management. Computed tomography and high-resolution computed tomography have identified bronchiectasis in individuals with HIV and alpha-1-antitrypsin deficiency. Early identification of predisposing disorders and aggressive management of symptoms has already been demonstrated by prolonged survival and decreased morbidity in cystic fibrosis patients, and similar management may benefit other populations with bronchiectasis. New treatments such as recombinant human DNase have been shown to improve pulmonary function and quality of life in cystic fibrosis patients and may prove useful in other chronic inflammatory lung disease.",
author = "Moreschi, {M. A.} and Stanley Fiel",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "1",
pages = "119--124",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Moreschi, MA & Fiel, S 1995, 'An update on bronchiectasis.', Current Opinion in Pulmonary Medicine, vol. 1, no. 2, pp. 119-124.

An update on bronchiectasis. / Moreschi, M. A.; Fiel, Stanley.

In: Current Opinion in Pulmonary Medicine, Vol. 1, No. 2, 01.01.1995, p. 119-124.

Research output: Contribution to journalReview article

TY - JOUR

T1 - An update on bronchiectasis.

AU - Moreschi, M. A.

AU - Fiel, Stanley

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Bronchiectasis is associated with heterogeneous predisposing conditions that cause abnormal dilatation and persistent inflammation in the bronchial tree and lung parenchyma. The disease remains a common cause of significant morbidity and mortality, especially when associated with hereditary disorders such as cystic fibrosis, ciliary dyskinesia, and immunodeficiency states. Recent investigations have focused on the inflammatory mediators involved in the pathogenesis of bronchiectasis. High-resolution computed tomography is now the diagnostic modality of choice and may also contribute to clinical management. Computed tomography and high-resolution computed tomography have identified bronchiectasis in individuals with HIV and alpha-1-antitrypsin deficiency. Early identification of predisposing disorders and aggressive management of symptoms has already been demonstrated by prolonged survival and decreased morbidity in cystic fibrosis patients, and similar management may benefit other populations with bronchiectasis. New treatments such as recombinant human DNase have been shown to improve pulmonary function and quality of life in cystic fibrosis patients and may prove useful in other chronic inflammatory lung disease.

AB - Bronchiectasis is associated with heterogeneous predisposing conditions that cause abnormal dilatation and persistent inflammation in the bronchial tree and lung parenchyma. The disease remains a common cause of significant morbidity and mortality, especially when associated with hereditary disorders such as cystic fibrosis, ciliary dyskinesia, and immunodeficiency states. Recent investigations have focused on the inflammatory mediators involved in the pathogenesis of bronchiectasis. High-resolution computed tomography is now the diagnostic modality of choice and may also contribute to clinical management. Computed tomography and high-resolution computed tomography have identified bronchiectasis in individuals with HIV and alpha-1-antitrypsin deficiency. Early identification of predisposing disorders and aggressive management of symptoms has already been demonstrated by prolonged survival and decreased morbidity in cystic fibrosis patients, and similar management may benefit other populations with bronchiectasis. New treatments such as recombinant human DNase have been shown to improve pulmonary function and quality of life in cystic fibrosis patients and may prove useful in other chronic inflammatory lung disease.

UR - http://www.scopus.com/inward/record.url?scp=15444343894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444343894&partnerID=8YFLogxK

M3 - Review article

C2 - 15786601

AN - SCOPUS:15444343894

VL - 1

SP - 119

EP - 124

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 2

ER -